{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T11:58:51Z","timestamp":1793361531955,"version":"4.5.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Pretreatment of HIV drug resistance among children living with HIV (CLHIV) can compromise antiretroviral therapy (ART) effectiveness. Resistance may be transmitted directly from mothers or acquired following exposure to antiretrovirals consumed through breastfeeding or administered as prophylaxis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We performed resistance testing in children aged &lt;3 years, newly diagnosed with HIV in Western Cape, South Africa (2021\u20132022), who either (1) acquired HIV via possible breastfeeding transmission from mothers who received ART (any regimen) during pregnancy\/postpartum and\/or (2) were exposed to protease inhibitors or integrase strand transfer inhibitors (INSTIs) in utero. Possible breastfeeding transmission was defined as testing HIV-polymerase chain reaction positive at age &gt;28 days, after previously testing negative. We used surveillance drug\u2013resistance mutation lists to define mutations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>We included 135 CLHIV. Most mothers started ART prepregnancy (73%). Overall, 57% (77\/135) of children had resistance mutations detected. Nonnucleoside reverse transcriptase inhibitor\u2013associated, nucleoside reverse transcriptase inhibitor\u2013associated, protease inhibitor\u2013associated and INSTI-associated mutations were found in 55% (74\/135), 10% (13\/135), &lt;1% (1\/135) and &lt;1% (1\/122) of children tested, respectively. One child with breastfeeding transmission had high-level INSTI resistance detected at HIV diagnosis, aged 18 months (E138K and G118R mutations).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Although not clinically relevant, nonnucleoside reverse transcriptase inhibitor\u2013associated mutations were common. Dolutegravir is currently the preferred first-line treatment for adults and CLHIV age \u22654 weeks, and although very low INSTI resistance levels have been observed in adults, limited data exist on genotyping the integrase region in children. Pretreatment INSTI resistance in children is likely to be unusual, but future surveillance, including longitudinal studies with paired mother-child resistance testing, is needed.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000004482","type":"journal-article","created":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T20:01:06Z","timestamp":1722369666000},"page":"970-976","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["HIV Drug Resistance in Newly Diagnosed Young Children in the Western Cape, South Africa"],"prefix":"10.1097","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2453-6219","authenticated-orcid":false,"given":"Kim","family":"Anderson","sequence":"first","affiliation":[{"name":"From the Centre for Infectious Disease Epidemiology and Research, School of Public Health, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert","family":"van Zyl","sequence":"additional","affiliation":[{"name":"Division of Medical Virology, National Health Laboratory Service and Tygerberg Hospital, Stellenbosch University, Stellenbosch, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nei-Yuan","family":"Hsiao","sequence":"additional","affiliation":[{"name":"Division of Medical Virology, National Health Laboratory Service and Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilda","family":"Claassen","sequence":"additional","affiliation":[{"name":"Division of Medical Virology, National Health Laboratory Service and Tygerberg Hospital, Stellenbosch University, Stellenbosch, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Mudaly","sequence":"additional","affiliation":[{"name":"Service Priorities Coordination, Western Cape Department of Health and Wellness, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1557-6908","authenticated-orcid":false,"given":"Jacqueline","family":"Voget","sequence":"additional","affiliation":[{"name":"Service Priorities Coordination, Western Cape Department of Health and Wellness, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa","family":"Heekes","sequence":"additional","affiliation":[{"name":"Health Intelligence, Western Cape Department of Health and Wellness, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Kalk","sequence":"additional","affiliation":[{"name":"From the Centre for Infectious Disease Epidemiology and Research, School of Public Health, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Phelanyane","sequence":"additional","affiliation":[{"name":"Health Intelligence, Western Cape Department of Health and Wellness, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Boulle","sequence":"additional","affiliation":[{"name":"From the Centre for Infectious Disease Epidemiology and Research, School of Public Health, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa"},{"name":"Health Intelligence, Western Cape Department of Health and Wellness, Cape Town, South Africa"},{"name":"Division of Public Health Medicine, School of Public Health, University of Cape Town, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayathri","family":"Sridhar","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, Durham, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leigh","family":"Ragone","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, Durham, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vani","family":"Vannappagari","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, Durham, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary-Ann","family":"Davies","sequence":"additional","affiliation":[{"name":"From the Centre for Infectious Disease Epidemiology and Research, School of Public Health, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa"},{"name":"Health Intelligence, Western Cape Department of Health and Wellness, Cape Town, South Africa"},{"name":"Division of Public Health Medicine, School of Public Health, University of Cape Town, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,7,23]]},"reference":[{"key":"R1-20250614","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/jac\/dkv080","article-title":"Is infant exposure to antiretroviral drugs during breastfeeding quantitatively important? A systematic review and meta-analysis of pharmacokinetic studies.","volume":"70","author":"Waitt","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"R2-20250614","doi-asserted-by":"crossref","first-page":"e1000430","DOI":"10.1371\/journal.pmed.1000430","article-title":"HIV-1 drug resistance emergence among breastfeeding infants born to HIV-infected mothers during a single-arm trial of triple-antiretroviral prophylaxis for prevention of mother-to-child transmission: a secondary analysis.","volume":"8","author":"Zeh","year":"2011","journal-title":"PLoS Med"},{"key":"R3-20250614","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1093\/cid\/cir008","article-title":"Initiation of antiretroviral treatment in women after delivery can induce multiclass drug resistance in breastfeeding HIV-infected infants.","volume":"52","author":"Fogel","year":"2011","journal-title":"Clin Infect Dis"},{"key":"R4-20250614","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/cid\/ciab744","article-title":"Maternal human immunodeficiency virus (HIV) drug resistance is associated with vertical transmission and is prevalent in infected infants.","volume":"74","author":"Boyce","year":"2022","journal-title":"Clin Infect Dis"},{"key":"R5-20250614","doi-asserted-by":"crossref","first-page":"e1200","DOI":"10.1093\/cid\/ciaa1861","article-title":"Infant exposure to dolutegravir through placental and breast milk transfer: a population pharmacokinetic analysis of DolPHIN-1.","volume":"73","author":"Dickinson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R6-20250614","article-title":"The Western Cape consolidated guidelines for HIV treatment: prevention of mother-to-child transmission of HIV (PMTCT), children, adolescents and adults.","year":"2020"},{"key":"R7-20250614","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jviromet.2008.07.008","article-title":"A genotypic assay for the amplification and sequencing of integrase from diverse HIV-1 group M subtypes.","volume":"153","author":"Van Laethem","year":"2008","journal-title":"J Virol Methods"},{"key":"R8-20250614","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jviromet.2015.07.005","article-title":"The use of dried blood spot specimens for HIV-1 drug resistance genotyping in young children initiating antiretroviral therapy.","volume":"223","author":"Salimo","year":"2015","journal-title":"J Virol Methods"},{"key":"R9-20250614","article-title":"Calibrated population resistance tool."},{"key":"R10-20250614","doi-asserted-by":"crossref","first-page":"e4724","DOI":"10.1371\/journal.pone.0004724","article-title":"Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update.","volume":"4","author":"Bennett","year":"2009","journal-title":"PLoS One"},{"key":"R11-20250614","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/jac\/dkz417","article-title":"Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance.","volume":"75","author":"Tzou","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"R12-20250614","first-page":"1143","article-title":"Data Centre Profile: The Provincial Health Data Centre of the Western Cape Province, South Africa.","volume":"4","author":"Boulle","year":"2019","journal-title":"Int J Popul Data Sci"},{"key":"R13-20250614","first-page":"07","article-title":"Record linkage for routinely collected health data in an African health information exchange.","volume":"8","author":"Mutemaringa","year":"2023","journal-title":"Int J Popul Data Sci"},{"key":"R15-20250614","article-title":"European AIDS Clinical Society (EACS) Guidelines, Version 12.0","year":"2023"},{"key":"R16-20250614","doi-asserted-by":"crossref","first-page":"e284","DOI":"10.1016\/S2352-3018(23)00047-4","article-title":"Implementation and outcomes of dolutegravir-based first-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort study.","volume":"10","author":"Dorward","year":"2023","journal-title":"Lancet HIV"},{"key":"R17-20250614","article-title":"The Western Cape consolidated guidelines for HIV treatment: prevention of mother- to- child transmission of HIV (PMTCT), children, adolescents and adults 2015."},{"key":"R18-20250614","article-title":"2023 ART clinical guidelines for the management of HIV in adults, pregnancy and breastfeeding, adolescents, children, infants and neonates.","year":"2023"},{"key":"R19-20250614","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jac\/dkw463","article-title":"Alarming increase in pretreatment HIV drug resistance in children living in sub-Saharan Africa: a systematic review and meta-analysis.","volume":"72","author":"Boerma","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"R20-20250614","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QAI.0000000000001553","article-title":"High prevalence of HIV drug resistance among newly diagnosed infants aged <18 months: results from a nationwide surveillance in Nigeria.","volume":"77","author":"Inzaule","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R21-20250614","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1097\/QAD.0000000000001446","article-title":"Persistence of HIV drug resistance among South African children given nevirapine to prevent mother-to-child-transmission.","volume":"31","author":"Kanthula","year":"2017","journal-title":"AIDS"},{"key":"R22-20250614","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1097\/QAD.0000000000001569","article-title":"HIV drug resistance in infants increases with changing prevention of mother-to-child transmission regimens.","volume":"31","author":"Poppe","year":"2017","journal-title":"AIDS"},{"key":"R23-20250614","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1093\/cid\/cix1104","article-title":"Human immunodeficiency virus antiretroviral resistance and transmission in mother-infant pairs enrolled in a large perinatal study.","volume":"66","author":"Yeganeh","year":"2018","journal-title":"Clin Infect Dis"},{"key":"R24-20250614","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1097\/QAD.0000000000002614","article-title":"High nonnucleoside reverse transcriptase inhibitor resistance levels in HIV-1-infected Zambian mother-infant pairs.","volume":"34","author":"Bennett","year":"2020","journal-title":"AIDS"},{"key":"R25-20250614","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1186\/s12879-019-4339-y","article-title":"Prevalence of HIV-1 drug resistance amongst newly diagnosed HIV-infected infants age 4\u20138 weeks, enrolled in three nationally representative PMTCT effectiveness surveys, South Africa: 2010, 2011\u201312 and 2012\u201313.","volume":"19","author":"Hunt","year":"2019","journal-title":"BMC Infect Dis"},{"key":"R26-20250614","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/INF.0000000000002270","article-title":"High levels of HIV-1 drug resistance in children who acquired HIV Infection through mother to child transmission in the era of option B+, Haiti, 2013 to 2014.","volume":"38","author":"Louis","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"R27-20250614","first-page":"e2","article-title":"Factors associated with vertical transmission of HIV in the Western Cape, South Africa: a retrospective cohort analysis.","volume":"27","author":"Anderson","year":"6235","journal-title":"J Int AIDS Soc"},{"key":"R28-20250614","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1097\/QAD.0000000000003653","article-title":"First case report of a perinatally HIV-infected infant with HIV resistance to dolutegravir associated with tenofovir\/lamivudine\/dolutegravir use in mothers.","volume":"37","author":"Francois","year":"2023","journal-title":"AIDS"},{"key":"R29-20250614","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/FTD.0000000000000735","article-title":"Therapeutic drug monitoring of HIV antiretroviral drugs in pregnancy: a narrative review.","volume":"42","author":"O\u2019Kelly","year":"2020","journal-title":"Ther Drug Monit"},{"key":"R30-20250614","article-title":"Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach.","year":"2021"},{"key":"R31-20250614","article-title":"HIV drug resistance report","year":"2021"},{"key":"R32-20250614","doi-asserted-by":"crossref","first-page":"e1002895","DOI":"10.1371\/journal.pmed.1002895","article-title":"Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: a randomised trial (DolPHIN-1 study).","volume":"16","author":"Waitt","year":"2019","journal-title":"PLoS Med"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004482","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T23:05:05Z","timestamp":1749942305000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,23]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000004482","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,23]]}}}